Skip to main content
Equibles

MOLBIO · Molbio Diagnostics Limited

Use MOLBIO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MOLBIO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
1,494.80 INR +100.20 (+7.18%) At close · Nov 13
Rebalance outlook locked
Volume · Nov 13 174.18K Avg daily vol (3M) 381.02K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Investor day
Close1,494.80 INR Open1,404.05 INR Day1,396.60–1,544.15 INR Available close range1,032.40–1,573.50 INR Avg vol 30d171K Last earningsNov 5, 2026 DataAug 2026–Nov 2026

The closing range uses available history since Aug 17, 2026; less than a full year is stored.

Latest documents

2026
Nov 5
Earnings call
Revenue dips as FY27 growth guidance remains intact

Molbio Diagnostics reported H1 FY27 INR667 crores in operating revenue versus INR680 crores, with INR153 crores EBITDA at a 23% margin and INR60 crores PAT. Management retained FY27 guidance for 25% top-line growth and a 24% to 25% EBITDA margin.

8 source passages
Thank you. Good evening, everyone, and thank you for joining us on the Q2 and H1 FY27 results conference call of Molbio Diagnostics Limited. On a consolidated basis, we delivered revenue from operations of INR667 crores in H1 FY27 versus INR680 crores in H1 of last year. Our EBITDA for H1 FY27 is INR153 crores, which represents a margin of 23% of total revenue. Our PAT for H1 FY27 is INR60 crores. So from a management guidance perspective, we are on track for that. So from a management guidance perspective, we see that we are on track for that. And with that, thank you all for attending our Q2 earnings call for fiscal 2027. And just to reiterate, as Mr. Sriram had mentioned, we believe that in terms of our model and in terms of our growth and in terms of our guidance, we continue to remain focused in terms of targeting the 25% top line growth for the current fiscal with about a 24% to 25% EBITDA margin. Open the document at this passage
All documents

Technicals

trend & momentum for long-term holders illustrative — not investment advice
Price context
position in its available closing range
Range low 1,032.40 INR Now 1,494.80 INR · 85% Range high 1,573.50 INR
vs 50-day avg +12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Performance

5D 20D 120D MTD YTD
XBOM:MOLBIO +11.5% +4.7% — +17.3% —

Exchange listing

Market
XBOM
Ticker
MOLBIO
ISIN
INE869T01028
Security
Ordinary share
Trading currency
INR

Company

Website
https://www.molbiodiagnostics.com/
Investor relations
https://www.molbiodiagnostics.com/investors/

Other listings of this company

Share classes and depositary receipts can have different prices and dividends.

Recent dividends

No verified dividend payments are available for this listing yet.

Upcoming investor events

No upcoming investor events are listed for this company yet.

Earnings calls

  • Earnings call · Q2 2027 2026-11-05 Transcript
    Earnings Call for the Quarter Ended September 30, 2026
  • Earnings call · Q1 2027 2026-09-08 Transcript
    Earnings Call for the Quarter Ended June 30, 2026